The cannabis industry seems to have a pessimistic mantra these days: Bad news for one company is bad news for the entire industry. The canceled MedMen-PharmaCann merger is a prime example of this.
But the reality is, cannabis is still a brand-new industry. Conflicting regulations in the U.S. and slow-moving regulations in Canada have a big impact on these burgeoning cannabis companies. And that should be priced into the market. Fortunately, bad news brings buying opportunities.